WAVE Life Sciences Ltd
WVE6.615USD
+0.415+6.69%
Fechamento 03/30, 16:00（ET）Cotações atrasadas em 15 min
138.47MValor de mercado
PerdaP/L TTM
Mais detalhes de WAVE Life Sciences Ltd Empresa
Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
Informações de WAVE Life Sciences Ltd
Código da empresaWVE
Nome da EmpresaWAVE Life Sciences Ltd
Data de listagemNov 11, 2015
CEOBolno (Paul B)
Número de funcionários287
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 11
Endereço7 Straits View
Cidade
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísSingapore
Código postal018936
Telefone6562363388
Sitehttps://www.wavelifesciences.com/
Código da empresaWVE
Data de listagemNov 11, 2015
CEOBolno (Paul B)
Executivos da empresa WAVE Life Sciences Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Chandra Vargeese, Ph.D.
Dr. Chandra Vargeese, Ph.D.
Chief Technology Officer, Head - Platform Discovery Sciences
Chief Technology Officer, Head - Platform Discovery Sciences
344.71K
+12.30%
Mr. Kyle Moran
Mr. Kyle Moran
Chief Financial Officer
Chief Financial Officer
103.00K
+40.81%
Dr. Christopher John Francis, Ph.D.
Dr. Christopher John Francis, Ph.D.
Senior Vice President - Corporate Development, Head - Emerging Areas
Senior Vice President - Corporate Development, Head - Emerging Areas
36.87K
--
Ms. Heidi L. Wagner, J.D.
Ms. Heidi L. Wagner, J.D.
Independent Director
Independent Director
28.82K
--
Ms. Aik Na Tan
Ms. Aik Na Tan
Independent Director
Independent Director
25.40K
-59.01%
Mr. Ken Takanashi
Mr. Ken Takanashi
Independent Director
Independent Director
23.94K
+32.69%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Chairman of the Board
Independent Chairman of the Board
12.70K
-50.75%
Dr. Paul B. Bolno, M.D.
Dr. Paul B. Bolno, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Gregory L. (Greg) Verdine, Ph.D.
Dr. Gregory L. (Greg) Verdine, Ph.D.
Director
Director
--
--
Dr. Peter Kolchinsky, Ph.D.
Dr. Peter Kolchinsky, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Chandra Vargeese, Ph.D.
Dr. Chandra Vargeese, Ph.D.
Chief Technology Officer, Head - Platform Discovery Sciences
Chief Technology Officer, Head - Platform Discovery Sciences
344.71K
+12.30%
Mr. Kyle Moran
Mr. Kyle Moran
Chief Financial Officer
Chief Financial Officer
103.00K
+40.81%
Dr. Christopher John Francis, Ph.D.
Dr. Christopher John Francis, Ph.D.
Senior Vice President - Corporate Development, Head - Emerging Areas
Senior Vice President - Corporate Development, Head - Emerging Areas
36.87K
--
Ms. Heidi L. Wagner, J.D.
Ms. Heidi L. Wagner, J.D.
Independent Director
Independent Director
28.82K
--
Ms. Aik Na Tan
Ms. Aik Na Tan
Independent Director
Independent Director
25.40K
-59.01%
Mr. Ken Takanashi
Mr. Ken Takanashi
Independent Director
Independent Director
23.94K
+32.69%
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qui, 5 de mar
Atualizado em: qui, 5 de mar
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
GSK plc
9.69%
RA Capital Management, LP
9.67%
Fidelity Management & Research Company LLC
7.25%
BlackRock Institutional Trust Company, N.A.
5.32%
Adage Capital Management, L.P.
5.20%
Outro
62.87%
Investidores
Investidores
Proporção
GSK plc
9.69%
RA Capital Management, LP
9.67%
Fidelity Management & Research Company LLC
7.25%
BlackRock Institutional Trust Company, N.A.
5.32%
Adage Capital Management, L.P.
5.20%
Outro
62.87%
Tipos de investidores
Investidores
Proporção
Investment Advisor
35.17%
Hedge Fund
22.63%
Investment Advisor/Hedge Fund
18.45%
Corporation
13.72%
Venture Capital
9.75%
Research Firm
1.81%
Individual Investor
0.54%
Bank and Trust
0.31%
Pension Fund
0.18%
Participação acionária institucional
Atualizado em: qua, 21 de jan
Atualizado em: qua, 21 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q4
342
144.00M
77.83%
--
2025Q4
393
146.58M
80.21%
+2.16M
2025Q3
368
140.86M
88.47%
+5.01M
2025Q2
364
156.69M
98.46%
-1.61M
2025Q1
368
156.82M
101.38%
+1.16M
2024Q4
342
152.89M
100.27%
+6.14M
2024Q3
306
144.44M
97.59%
+25.71M
2024Q2
274
116.00M
94.13%
+429.46K
2024Q1
255
115.83M
95.69%
+2.66M
2023Q4
240
115.18M
98.42%
+19.70M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
GSK plc
18.25M
9.98%
+1.47M
+8.76%
Dec 11, 2025
RA Capital Management, LP
18.22M
9.97%
--
--
Dec 11, 2025
Fidelity Management & Research Company LLC
4.29M
2.35%
+3.67M
+592.96%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.73M
4.78%
-23.62K
-0.27%
Sep 30, 2025
Adage Capital Management, L.P.
14.57M
7.97%
-448.72K
-2.99%
Sep 30, 2025
Maverick Capital, Ltd.
8.39M
4.59%
+130.17K
+1.58%
Sep 30, 2025
T. Rowe Price Associates, Inc.
3.91M
2.14%
-1.17M
-23.10%
Sep 30, 2025
Driehaus Capital Management, LLC
6.30M
3.45%
-233.46K
-3.57%
Sep 30, 2025
Shin Nippon Biomedical Laboratories Ltd
5.71M
3.12%
--
--
Jun 06, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
State Street SPDR S&P Pharmaceuticals ETF
1.81%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.34%
Global X Genomics & Biotechnology ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
iShares U.S. Pharmaceuticals ETF
0.41%
First Trust Multi-Manager Small Cap Opportunities ETF
0.26%
iShares Micro-Cap ETF
0.19%
Franklin Genomic Advancements ETF
0.19%
ProShares Ultra Nasdaq Biotechnology
0.15%
Invesco Nasdaq Biotechnology ETF
0.14%
Ver Mais
State Street SPDR S&P Pharmaceuticals ETF
Proporção1.81%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.34%
Global X Genomics & Biotechnology ETF
Proporção1.25%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.85%
iShares U.S. Pharmaceuticals ETF
Proporção0.41%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporção0.26%
iShares Micro-Cap ETF
Proporção0.19%
Franklin Genomic Advancements ETF
Proporção0.19%
ProShares Ultra Nasdaq Biotechnology
Proporção0.15%
Invesco Nasdaq Biotechnology ETF
Proporção0.14%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
